Patterns and predictors of locoregional recurrence following neoadjuvant chemoradiation for esophageal cancer.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 173-173
Author(s):  
Aaron Udell Blackham ◽  
Will Jin ◽  
Khaldoun Almhanna ◽  
Jacques-Pierre Fontaine ◽  
Sarah E. Hoffe ◽  
...  

173 Background: Despite neoadjuvant chemoradiation (nCRT) followed by esophagectomy for locally advanced esophageal cancer, locoregional recurrences (LRR) are common. Specific risk factors for LRR have yet to be identified. Methods: Patients with esophageal cancer who were treated with nCRT and esophagectomy were identified from a single institution, prospectively maintained database(1996-2013). Timing and locations of recurrences were described and predicting factors of LRR were analyzed. Results: Out of 456 patients treated with nCRT for esophageal cancer, 167 patients developed known recurrence. Locoregional and distant recurrences were observed in 69(15.1%) and 140(30.9%) patients, respectively. Median recurrence-free survival was 38.5 months with a median follow-up of 30.4 months. Sixty-eight patients(40.7%) developed recurrence at multiple sites. The median time to recurrence was 13.5 months and survival following recurrence was only 8.0 months in the 27 patients(16.2%) with solitary LRR. Overall survival in patients with solitary LLR was 23.6 months, compared to 20.8 months in all patients who developed distant recurrence. Univariate analysis identified lymph node ratio > 0.5(OR 2.42, p = 0.030), non-complete pathologic response(OR 1.90, p = 0.022), positive margins(OR 3.58, p = 0.028) and lymphovascular invasion(OR 2.82, p = 0.001) as significant predicting factors for LRR. While perineural invasion(p = 0.055), nodal stage(0.053) and use of adjuvant therapy(p = 0.060) approached significance, other factors such as tumor stage, type of surgery (Ivor-Lewis vs transhiatal), radiation dose and use of IMRT were not significant predictors of LRR. Only lymphovascular invasion was an independent predictor of LRR. Conclusions: Prognosis following LRR in patients with esophageal cancer treated with nCRT is poor but is better than in patients who develop distant recurrence. High lymph node ratio, positive margin status, non-complete pathologic response and the presence of lymphovascular invasion are predictive of LRR following nCRT for esophageal cancer.

2009 ◽  
Vol 136 (5) ◽  
pp. A-900
Author(s):  
Peter K. Baier ◽  
Frank Makowiec ◽  
Patrick Hörmann ◽  
Axel zur Hausen ◽  
Ulrich T. Hopt

Tumor Biology ◽  
2014 ◽  
Vol 36 (4) ◽  
pp. 2335-2341 ◽  
Author(s):  
Nana Wang ◽  
Yibin Jia ◽  
Jianbo Wang ◽  
Xintong Wang ◽  
Cihang Bao ◽  
...  

2012 ◽  
Vol 94 (5) ◽  
pp. 1643-1651 ◽  
Author(s):  
Castigliano M. Bhamidipati ◽  
George J. Stukenborg ◽  
Christopher J. Thomas ◽  
Christine L. Lau ◽  
Benjamin D. Kozower ◽  
...  

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 101-101
Author(s):  
Yaping Xu ◽  
Xiaojiang Sun ◽  
Yuanda Zheng

101 Background: Though postoperative radiation for esophageal cancer is offered in selected cases, there is conflicting evidence as to whether it improves overall survival (OS). We performed a retrospective investigation to analyze the prognosis impact of adjuvant radiation in a large cohort of patients. Methods: From 2002 to 2008, 545 patients underwent radical esophagectomy (R0) with or without postoperative radiation were eligible for retrospectively analysis. Patients were grouped to surgery only (n=346) and surgery plus postoperative radiation therapy (PORT) (n=199). Radiation dose was 50 Gy in 25 fractions. Kaplan-Meier and Cox regression analysis were used to compare OS. Results: The use of PORT was associated with significantly improved OS ( p =0.006). The median OS was 31 months in the group receiving PORT and 21 months in the group undergoing surgery alone. The addition of PORT improved OS at 3 years from 38.3 to 45.8% compared with surgery alone. For American Joint Committee on Cancer (AJCC) stage III esophageal cancer (T1-2N2M0, T3N1-2M0, T4N1-3M0), there was significant improvement on OS ( p < 0.001) in PORT group, for not only metastatic lymph-node ratio <0.25 ( p = 0.047), but also metastatic lymph-node ratio >0.25 ( p = 0.013). However, for stages IIB disease (T1-2N1M0) there was no significant differences. Conclusions: This large population-based analysis supports the use of PORT for pathologic lymph nodes positive stage III esophageal cancer. Our results suggest that a subset of such patients may benefit from aggressive local therapy.


Sign in / Sign up

Export Citation Format

Share Document